08:54 AM EST - BioVaxys Technology Corp : Along with SpayVac-for-Wildlife, Inc. jointly announce that SpayVac has partnered with a world leader in the aquaculture space to field test single-injection, long-lasting immuno-contraceptive vaccines in the commercial aquatic farming industry, specifically in farmed rainbow trout. SpayVac utilizes a patented liposome-based antigen delivery platform technology licensed from BioVaxys and has demonstrated a robust and sustained immune response in several species. BioVaxys Technology Corp
shares C.BIOV are trading up one cent at $0.08.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACNX&qmodStoryID=8178455910379256
